Institutional Repository in Medical Sciences
(IRMS – Nicolae Testemițanu SUMPh)

Etiology, pathogenesis, diagnosis and treatment of ovarian cancer

Show simple item record

dc.contributor.author Cheacir, Anastasia
dc.date.accessioned 2024-10-28T12:50:28Z
dc.date.accessioned 2024-11-18T17:30:36Z
dc.date.available 2024-10-28T12:50:28Z
dc.date.available 2024-11-18T17:30:36Z
dc.date.issued 2024
dc.identifier.citation CHEACIR, Anastasia. Etiology, pathogenesis, diagnosis and treatment of ovarian cancer. In: MedEspera: the 10th Intern. Medical Congress for Stud. and Young Doctors, 24-27 April 2024: abstract book. Chișinău, 2024, p. 218. ISBN 978-9975-3544-2-4. en_US
dc.identifier.isbn 978-9975-3544-2-4
dc.identifier.uri https://medespera.md/en/books?page=10
dc.identifier.uri https://repository.usmf.md/handle/20.500.12710/28634
dc.description Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu”, Chişinău, Republica Moldova en_US
dc.description.abstract Introduction. The 5th most common cause of death among women is caused by ovarian cancer. According to the American Cancer Society, the risk of being diagnosed with ovarian cancer throughout life for women is 1 in 78. In the US, it is expected to be detected in 2023, 19,710 new cases of ovarian cancer and about 13,270 deaths from ovarian cancer. Aim of study. To study and analyze the current articles on etiology, pathogenesis, diagnosis and treatment of ovarian cancer. Methods and materials. This abstract was done by exploring and analyzing medical publications from PubMed, Medscape, NCBI, MEDLINE. Results. Ovarian cancer is detected at an early stage only in 20-25%. Most often it is diagnosed in postmenopausal women. The primary risk factor is a family history of ovarian or breast cancer. First-line investigations include detection of CA-125 marker in blood and transvaginal ultrasonography. In addition, abdominal and pelvic CT, PET scanning and MRI of the pelvic region can be used to visualize the extension of the tumor. Currently, ovarian cancer treatment consists of combining surgery with chemotherapy. According to the latest data, laparoscopic surgery is preferred, as it is less invasive and has a faster recovery than debulking operations. Tumor progression and tumor recurrence occurs more frequently in advanced stages. Conclusion. Currently, ovarian cancer remains one of the most common causes of lethality in women, the main cause being the lack of effective strategies for early detection of ovarian cancer. The latest studies show that median survival for stage 1 ovarian cancer is between 70% and 90%, and for stage 4 it is less than 6%. According to the American Cancer Society, the risk of be ing diagnosed with ovarian cancer throughout life for women is 1 in 78. In the US, it is expect ed to be detected in 2023, 19,710 new cases of ovarian cancer and about 13,270 deaths from ovari an cancer. Aim of study. To study and analyze the current articles on etiology, pathogenesis, diagnosis and treatment of ovarian cancer. Methods and materials. This abstract was done by exploring and analyzing medical publications from PubMed, Medscape, NCBI, MEDLINE. Results. Ovarian cancer is detected at an early stage only in 20-25% . Most often it is diagnosed in postmenopausal women. The primary risk factor is a family hi story of ovarian or breast cancer. First-line investigations include detection of CA-125 marker in blood and transvaginal ultrasonography. In addition, abdominal and pelvic CT, PET scanning and MRI of the pelvic region can be used to visualize the extension of the tumor . Currently, ovarian cancer treatment consists of combining surgery with chemotherapy. According to the latest data, laparoscopic surgery is preferred, as it is less invasive and has a fas ter recovery than debulking operations. Tumor progression and tumor recurrence occurs more frequentl y in advanced stages. Conclusion. Currently, ovarian cancer remains one of the most com mon causes of lethality in women, the main cause being the lack of effective strat egies for early detection of ovarian cancer. The latest studies show that median survival for stage 1 ov arian cancer is between 70% and 90%, and for stage 4 it is less than 6%. en_US
dc.publisher Instituţia Publică Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu” din Republica Moldova en_US
dc.relation.ispartof MedEspera: The 10th International Medical Congress for Students and Young Doctors, 24-27 April 2024, Chișinău, Republic of Moldova en_US
dc.title Etiology, pathogenesis, diagnosis and treatment of ovarian cancer en_US
dc.type Other en_US


Files in this item

This item appears in the following Collection(s)

  • MedEspera 2024
    The 10th International Medical Congress for Students and Young Doctors, 24-27 April, 2024

Show simple item record

Search DSpace


Advanced Search

Browse

My Account

Statistics